Aprea Therapeutics, Inc. APRE
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. We have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | — | — | — | — | $23.9M | $37.9M | $21.0M | $14.2M | $13.4M | — |
| SG&A | $6.5M | $6.5M | $8.4M | $21.0M | $13.6M | $14.9M | $8.6M | $2.3M | $2.5M | — |
| Total operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M | $52.8M | $29.5M | $16.5M | $15.9M | — |
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M | — | — | — | — | — |
| Pre-tax income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M | -$53.5M | -$28.1M | -$15.5M | -$15.2M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M | -$53.5M | -$28.1M | -$15.5M | -$15.2M | — |
| EPS, basic | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 | -4.67 | — | — | — |
| EPS, diluted | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 | -4.67 | -13.45 | -13.17 | — |
| Shares, diluted (wtd. avg.) | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 6.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M | $89.0M | $130.1M | $65.7M | $24.4M | $13.7M |
| Total current assets | $15.6M | $23.6M | $22.5M | $30.2M | $56.6M | $92.4M | $133.0M | $66.0M | — | — |
| Property, plant and equipment | $59.8K | $81.5K | $88.4K | $2.3K | $23.9K | $38.5K | $41.6K | $24.4K | — | — |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M | $92.8M | $133.6M | $66.0M | — | — |
| Accounts payable | $713.7K | $1.4M | $1.7M | $842.8K | $1.8M | $4.5M | $2.2M | $1.7M | — | — |
| Total current liabilities | $2.8M | $3.4M | $4.4M | $3.2M | $7.3M | $15.3M | $9.1M | $4.9M | — | — |
| Total liabilities | — | — | — | $3.2M | $7.3M | $15.4M | $9.4M | $4.9M | — | — |
| Retained earnings | -$333.6M | -$321.0M | -$308.1M | -$293.8M | -$181.1M | -$144.0M | -$90.5M | -$62.5M | — | — |
| Total equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M | $77.4M | $124.2M | -$51.4M | -$35.8M | -$21.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M | -$41.8M | -$26.7M | -$15.3M | -$14.0M | — |
| Depreciation and amortisation | $21.7K | $22.3K | $7.1K | $4.4K | $12.8K | $28.8K | $11.1K | $8.3K | $7.9K | — |
| Capital expenditure | — | $15.5K | $93.1K | — | — | $25.7K | $30.9K | $3.7K | — | — |
| Investing cash flow | — | -$15.5K | -$93.1K | — | — | -$25.7K | -$30.9K | -$3.7K | — | — |
| Financing cash flow | $4.6M | $14.8M | $5.1M | $683.0K | $1.7M | $150.9K | $92.6M | $56.4M | $23.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-028068.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | — | -$15.2M | -$15.5M | -$28.1M | -$53.5M | -$37.1M | -$112.7M | -$14.3M | -$13.0M | -$12.6M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |